IVIEW announces successful completion of in-vitro virucidal study of IVIEW-1503, a safe, non-toxic and long-lasting Povidone Iodine nasal spray for the prevention and treatment of COVID-19

Doylestown, Pennsylvania–IVIEW Therapeutics Inc., an innovative clinical stage specialty pharmaceutical company is proud to announce the successful completion of in-vitro virucidal study of IVIEW-1503, a safe, non-toxic and long-acting Povidone Iodine nasal spray for the prevention and treatment of COVID-19. The result was published on bioRxiv preprint doi: https://doi.org/10.1101/2020.05.18.103184 titled “In-Vivo Toxicity Studies and In-Vitro Inactivation of SARS-CoV-2 by Povidone-iodine In-situ Gel Forming Formulations.”

The rising numbers of COVID-19 cases in the United States earlier this year has prompted IVIEW to develop a safe, non-toxic and long-acting Povidone Iodine nasal spray for the prevention and treatment of the COVID-19 infection to curb the spread of SARS-CoV-2 virus. In collaboration with Institute for Antiviral Research at Utah State University, an in-vitro virucidal assay test with IVIEW’s novel PVP-I formulation, IVIEW-1503, against SARS-CoV-2 virus had showed promising results of completed eradicated SARS-CoV-2 virus to non-detectable level within 2 minutes. Povidone-iodine (PVP-I) is known for its high virucidal efficacy especially against enveloped viruses.

The results have evidently demonstrated IVIEW-1503 as a potential virucidal agent in preventing and treating SARS-CoV-2 viral infection. In addition, the stable formulation showed minimal toxicity while delivering optimal effectiveness. IVIEW Therapeutics hopes to be able to further advance the product into clinical studies to aid healthcare front-liners and affected patients in fighting SARS-CoV-2. The long acting nasal spray can potentially lead to prophylaxis of COVID-19 infection through the nasal route. As U.S. still has low PPE supplies such as masks, PVP-I is a great alternative with its economically low price and safe component. The development of a dilute PVP-I nasal formulation would be a great asset in fighting the COVID-19 pandemic by treating and preventing further progression of the debilitating infection that may lead to dangerous symptoms.

About IVIEW Therapeutics Inc.

IView Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of ophthalmology therapeutics. IVIEW Therapeutics is headquartered in Pennsylvania Biotechnology Center of Bucks County with its China subsidiary located in Hengqin, Zhuhai city. For additional information on IView, please visit the Company’s website at www.iviewtherapeutics.com.

Pennsylvania Biotechnology Center at Bucks County
3805 Old Easton Road
Doylestown PA 18902 USA
Copyright © 2020 iVIEW Therapeutics, Inc. All rights reserved.